<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964806</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0799</org_study_id>
    <nct_id>NCT02964806</nct_id>
  </id_info>
  <brief_title>Development and Clinical Validation of Ketogen-based Therapeutic Diet for Pancreaticobiliary Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decreased bowel function and loss of appetite in patients who underwent pancreaticobiliary
      surgery contribute impaired nutritional status in postoperative period. It can also affect
      perioperative and oncologic outcomes negatively. Therefore it is important to improve
      nutritional status in postoperative period by supply tailor-made optimal diets. The
      investigators have developed customized postoperative diets for pancreaticobiliary cancer
      patients. The investigators expect that customized diets for pancreaticobiliary patients
      will increase the food intake rate and contribute a improvement of perioperative outcomes
      and even oncologic outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Food Intake Rate(%) for postoperative diet</measure>
    <time_frame>3 days after the diet</time_frame>
    <description>Diet Intake Rate(%) will be examined by dietary satisfaction questionnaires.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ketogen-based Therapeutic Diet</condition>
  <condition>Pancreaticobiliary Cancer</condition>
  <arm_group>
    <arm_group_label>Ordinary Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ordinary Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Atkin's Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Modified Atkin's Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketogenic Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ketogenic Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ordinary Diet</intervention_name>
    <arm_group_label>Ordinary Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Modified Atkin's Diet</intervention_name>
    <arm_group_label>Modified Atkin's Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketogenic Diet</intervention_name>
    <arm_group_label>Ketogenic Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (age more than 19)

          -  Pancreaticobiliary cancer patient who is scheduled pancreaticoduodenectomy or distal
             pancreatectomy

          -  Pancreatic cancer / Duodenal cancer / Distal bile duct cancer / Ampulla of Vater
             cancer

        Exclusion Criteria:

          -  Patient who denied clinical trial

          -  Diabetes Mellitus(DM) patient with DM complication

          -  Hyperlipidemia patient with vascular co-morbidity

          -  Impaired renal function or renal failure (GFP&lt;90%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Moo Kang, MD</last_name>
      <phone>82-2-2228-2100</phone>
      <email>cmkang@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>November 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
